COSCIENS Biopharma Inc T.AEZ

Primary Symbol: T.AEZS

Healthcare Biotechnology

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.

TSX:AEZS - Post by User

COSCIENS Biopharma Inc

Bullboard Posts

Comment by slagheapon Oct 16, 2015 4:21pm

147 Views

Post# 24199878

RE:Management is

Here`s what is really troublng. Even CEO Dodd must realize he signed a deal that borders on destroying the company. Who would buy shares on the open market with these terms. The B warrants expire in October 2016 and from now to then will be a huge short position.

As of the record date for the meeting of Oct. 14, 2015, there were 544,179,214 issued and outstanding common shares and approximately 5.3 million issued and outstanding Series B share purchase warrants, representing approximately 17.7 per cent of the number originally issued.

Bullboard Posts

How Canadian investors can benefit from flow-through shares